The World ADC London Summit returns for its 16th edition from February 23–26, 2026, in London, bringing together the global antibody–drug conjugate (ADC) community for four days of intensive scientific exchange, strategic insight, and high-impact networking.
Recognized as Europe’s longest-standing and most definitive ADC forum, World ADC London 2026 convenes senior decision-makers from biopharma, clinical research, manufacturing, investment, and regulation to shape the future of precision oncology.
ADC innovation at a pivotal moment
As first-generation ADCs increasingly establish themselves as standards of care in oncology, the bioconjugate field is now entering a new phase of differentiation. The focus has shifted toward:
- Overcoming tumor resistance mechanisms, including Topoisomerase I (Topo1) resistance
- Unlocking novel payload and linker technologies
- Improving the translation of efficacious yet tolerable ADCs into the clinic
- Enhancing manufacturing robustness and supply-chain scalability
World ADC London 2026 is designed to address these challenges head-on, providing a comprehensive, end-to-end perspective on ADC discovery, development, and commercialization.
A truly end-to-end ADC programme
The 2026 agenda features five parallel content streams, covering the full ADC lifecycle:
- Discovery & ADC Design – differentiated payloads, linker chemistry, and next-generation constructs
- Preclinical & Translational Development – predictive models and early efficacy insights
- Clinical Lessons – real-world data, tolerability, and trial optimization
- Process & Analytical Development – CMC strategy, analytical innovation, and quality control
- Manufacturing & Supply Chain – scale-up, tech transfer, and commercial readiness
Together, these tracks provide a cohesive roadmap for pushing ADCs earlier in treatment lines and maximizing their therapeutic index.
What’s new for 2026
The 16th World ADC London Summit introduces several new and expanded elements, including:
- Patient and charity representation, in collaboration with Blood Cancer UK
- A globally diverse speaker faculty from Europe, North America, and Asia
- Increased focus on differentiated ADC payloads and design strategies
- First-time presentations from emerging innovators such as Adcoris Biopharma, ALX Oncology, and Salubris Bio
- Expanded participation from regulators, clinicians, and investors, strengthening cross-sector dialogue
These additions reflect the growing maturity of the ADC field and the need for integrated perspectives across science, medicine, and policy.
Who attends World ADC London
World ADC London 2026 is expected to unite:
- 700+ senior ADC industry attendees
- 240+ companies across biopharma, biotech, CDMOs, and service providers
- 110+ global expert speakers
- 14+ hours of dedicated networking, including structured one-on-one partnering
Attendees include representatives from leading organizations such as AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Roche, Johnson & Johnson, and many others shaping the ADC landscape.
Speaker highlights
The 2026 speaker faculty includes internationally recognized leaders in ADC research and development, such as:
- Paolo Tarantino – Clinical Research Fellow, Dana-Farber Cancer Institute
- Elaine Hurt – Executive Director, AstraZeneca
- Guillaume Bergthold – Executive Director, Clinical Development, Daiichi Sankyo
- Luisa Freitas dos Santos – Vice President, Global Clinical Supply Chain, GSK
- Alan Russell – VP Research & Head of R&D Technology and Innovation, Amgen
These and more than 100 additional experts will share lessons learned, emerging data, and forward-looking strategies.
Why World ADC London matters
As the ADC field evolves rapidly, World ADC London has become the place where:
- New scientific ideas are stress-tested
- Emerging technologies gain visibility
- Strategic partnerships are formed
- The next generation of ADC therapies takes shape
With a strong emphasis on collaboration, innovation, and translational impact, the summit plays a central role in advancing ADCs toward more precise, durable, and patient-centered cancer treatments.
Event details
- Event: 16th World ADC London Summit
- Dates: February 23–26, 2026
- Location: London, United Kingdom
- Format: In-person conference with structured partnering